Fifty 410 vs MEDVi: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Fifty 410 and MEDVi, measure by measure
| Measure | Fifty 410 | MEDVi |
|---|---|---|
| Tirzepatide, month to month | $199 (per 28-day cycle) | — |
| Tirzepatide, lowest printed | $149.50 (8-week program at $299, not in all states) | — |
| Semaglutide, month to month | $199 (per 28-day cycle) | — |
| Semaglutide, lowest printed | $199 (4-week program) | — |
| Dose pricing | priced by dose or not stated | not confirmed |
| Membership or program fee | none | not confirmed |
| Computed score | 23.5 of 40 (position 8 of 27) | 0 of 40 (position 21 of 27) |
| FDA warning letters | 721481 (2026-02-20) | 721455 (2026-02-20) |
| November 20 read | first-party read, changed | not readable Nov 20 |
Strengths and limitations: which fits whom
Fifty 410 bills every 28 days, which adds a 13th charge to the year. MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Fifty 410 | tirzepatide | — | $199 |
| Fifty 410 | semaglutide | — | $199 |
Regulatory record
FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Fifty 410 or MEDVi?
On compounded tirzepatide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible. On compounded semaglutide, only Fifty 410 prints a comparable month-to-month price, $199 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Do Fifty 410 and MEDVi charge a membership fee?
Fifty 410: no membership fee; MEDVi: not confirmed on November 20, 2026. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Fifty 410 and MEDVi medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Fifty 410 pricing page (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- FDA warning letter 721481 to Fifty 410 (dated 2026-02-20, posted 2026-03-03)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)